CD8A and breast carcinoma: Targeting the Vim-PGI&lt;sub&gt;2&lt;/sub&gt; Pathway Enhances CD8&lt;sup&gt;+&lt;/sup&gt; T Cell-Mediated Antitumor Immunity in Breast Cancer.